Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

39.99 +0.52 (+1.32%)
Streaming Delayed Price Updated: 12:18 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V.

< Previous 1 2 3 Next >
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
From QIAGEN
Via Business Wire
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
From QIAGEN N.V.
Via Business Wire
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
From QIAGEN N.V.
Via Business Wire
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
Via ACCESSWIRE
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN Issues 2021 Sustainability Report
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
From QIAGEN N.V.
Via Business Wire
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
From QIAGEN N.V.
Via Business Wire
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.